Crossmark

A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis

Crossref DOI link: https://doi.org/10.1016/j.reuma.2020.05.004

Published Print: 2021-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Jiménez-Morales, Alberto

Cáliz, Rafael

Aceituno, Susana

Prades, Miriam

Blanch, Carles
Funding

Funding for this research was provided by:

Novartis Farmacéutica
License Information

Text and Data Mining valid from 2021-11-01
More Information

This article is maintained by: Elsevier

Article Title: A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis

Journal Title: Reumatología Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reuma.2020.05.004

Content Type: article

Copyright: © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.